Title: Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches
Authors: COECKE SANDRAPELKONEN OLAVILEITE SOFIA BATISTABERNAUER ULRIKEBESSEMS JOSBOIS FREDERICGUNDERT-REMY URSULALOIZOU GEORGETESTAI EMANUELAZALDIVAR COMENGES JOSE'
Citation: TOXICOLOGY IN VITRO vol. 27 no. 5 p. 1570-1577
Publisher: PERGAMON-ELSEVIER SCIENCE LTD
Publication Year: 2013
JRC N°: JRC69640
ISSN: 0887-2333
URI: https://www.sciencedirect.com/science/article/pii/S0887233312001622
http://publications.jrc.ec.europa.eu/repository/handle/JRC69640
DOI: 10.1016/j.tiv.2012.06.012
Type: Articles in periodicals and books
Abstract: Toxicokinetics (TK) is the endpoint that informs about the penetration into and fate within the body of a toxic substance, including the possible emergence of metabolites. Traditionally, the data needed to understand those phenomena have been obtained in vivo. Currently, with a drive towards non-animal testing approaches, TK has been identified as a key element to integrate the results from in silico, in vitro and already available in vivo studies. TK is needed to estimate the range of target organ doses that can be expected from realistic human external exposure scenarios. This information is crucial for determining the dose/concentration range that should be used for in vitro testing. Vice versa, TK is necessary to convert the in vitro results, generated at tissue/cell or subcellular level, into dose response or potency information relating to the entire target organism, i.e. the human body (in vitro – in vivo extrapolation, IVIVE). Physiologically based toxicokinetic modelling (PBTK) is currently regarded as the most adequate approach to simulate human TK and extrapolate between in vitro and in vivo contexts. The fact that PBTK models are mechanism-based which allows them to be ‗generic‘ to a certain extent (various extrapolations possible) has been critical for their success so far. The need for high-quality in vitro and in silico data on absorption, distribution, metabolism as well as excretion (ADME) as input for PBTK models to predict human dose-response curves is currently a bottleneck for integrative risk assessment.
JRC Directorate:Health, Consumers and Reference Materials

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.